XI-B Antibody

Mechanism of Action

Factor XI (FXI) inhibitors selectively block coagulation pathways linked to thrombosis while preserving hemostasis. Key antibodies include:

These antibodies prolong activated partial thromboplastin time (APTT) without affecting prothrombin time (PT), reducing bleeding risks compared to traditional anticoagulants .

AB023 (Xisomab 3G3)

• Primate Thrombosis Model: Reduced platelet/fibrin accumulation by >75% in vascular grafts .

• Phase 1 Trial (NCT03097341):

  • Safety: No serious adverse events; 44% (7/16) treatment-emergent AEs vs. 60% (3/5) placebo .

  • Pharmacodynamics: Sustained ≈2× APTT prolongation for >1 month post-dose .

SHR-2004

• First-in-Human Study (NCT05369767):

  • Dosing: Single IV (0.1–1.0 mg/kg) or SC (0.5–4.5 mg/kg) .

  • Efficacy: Near-complete FXI inhibition at 1.0 mg/kg IV (APTT ≈3× baseline) .

  • Half-Life: 11.6–13.0 days .

Abelacimab

• Phase 3 Trials:

  • Indications: Atrial fibrillation, cancer-associated thrombosis .

  • Dosing: Monthly SC autoinjector (chronic) or IV + SC (acute) .

  • FDA Designations: Fast Track for cancer thrombosis (2022) and stroke prevention (2022) .

Comparative Advantages

• AB023: Unique inhibition of contact activation (FXIIa-driven) without impairing thrombin-mediated hemostasis .

• SHR-2004: Rapid, dose-dependent FXI suppression suitable for acute settings .

• Abelacimab: Monthly dosing and compatibility with antiplatelet therapies .

Ongoing Research and Challenges

• AB023: Further trials needed to validate efficacy in venous thromboembolism (VTE) and cardiovascular diseases .

• SHR-2004: Requires long-term safety monitoring despite promising phase 1 results .

• Abelacimab: Phase 3 trials will determine real-world bleeding risk in cancer patients .

Future Directions

Factor XI antibodies represent a paradigm shift in anticoagulation, particularly for patients with high bleeding risk. Ongoing studies aim to:

• Optimize dosing regimens for surgical and chronic settings.

• Explore combinations with antiplatelet agents .

• Validate biomarkers for personalized therapy .